Ready, set, grow: Lonza announces next big expansion

Lonza said it is planning to pump almost $1 billion to expand manufacturing capabilities in the U.S. and Switzerland. 

Under the new plans, the CDMO will grow its mammalian drug-substance manufacturing prowess with a new, large-scale plant in Visp, Switzerland complete with six 20,000L bioreactors in about 27,500 square-meters. The plant is slated for completion in 2024. 

The company also plans to build a 3,000-square meter plant in New Hampshire with up to eight 2,000L bioreactors that it plans to finish by 2023. 

All told, the company will invest $935 million into the expansion plans will create about 550 jobs across the two sites. 

Lonza also recently announced a plan to expand its drug substance manufacturing in Visp to support vaccine production for Moderna’s vaccine. The new 10-year agreement will add three production lines in Visp.